Summary:
Therafirst Medical Center is conducting a research study for individuals with HIV. This study is a phase 3 randomized double-blind, switch study to evaluate F/TAF in HIV-1 positive subjects who are virologically suppressed on regimens containing FTC/TDF.
Qualified Participants Must:
• Have a documented undetectable HIV Viral Load for greater than 6 months
Qualified Participants May Receive:
All testing, study visits, study medication and reimbursement for time and travel.